Is Your Medtech Market Strategy Ready Before FDA Authorization
An FDA submission can feel like the finish line. For many medtech companies, it becomes the center of gravity for months or years: test data, labeling, technical files, reviewer questions, quality documentation, and the next regulatory milestone. But authorization alone does not create market adoption. A device can clear a regulatory path and still struggle to gain clinical use, payer interest, sales traction, or investor confidence. The gap is rarely caused by one missed tactic. It often...
